ChinaAccelerated Patent ExaminationChina Patent OfficeCNIPAHong KongInventionsPrioritized Examination
4 January 2023

BREAKING NEWS: New Pilot Program for Hong Kong Applicants to get Accelerated Patent Examination in the Chinese Patent Office Starting January 1, 2023

by
Ms. Audrey Cheung
Ms. Jennifer Che

New year, new resolutions! The CNIPA has recently announced a pilot program that provides Hong Kong applicants the opportunity to expedite their patent applications filed in China. Starting 1 Jan 2023, Hong Kong permanent residents and entities legally registered in Hong Kong can request prioritized examination for their invention patent applications before the CNIPA. To be eligible, the patent application must be:

  1. an invention application filed directly in China or via national phase entry into China in the substantive examination stage;
  2. filed electronically;
  3. the invention belongs to a qualified technical field, such as internet, big data, cloud computing, biotechnology, environment protection, high-end technology manufacturing, new materials, energy conservation, and more—check out this document (Chinese only) to see the eligible IPC codes; and
  4. the applicant or at least one co-applicant must be (1) a Hong Kong permanent resident or (2) a company established under Companies Ordinance in Hong Kong or a legal entity or organization of other types in Hong Kong.

To request a prioritized examination, the applicant will need to submit a request form along with other required documents to the CNIPA at one of the representative offices in Guangdong or Shenzhen, by mail or in person. Of particular note, applicants must submit information about the existing technology in the field, i.e., known prior art, not unlike an Information Disclosure Statement (IDS) in the US. The applicant must appoint an agency to file the request for prioritized examination unless they have a permanent residence or business office in Mainland China.

Additional Notes:

  • Same Day Invention + UM Applications will generally not receive prioritized examination
  • All foreign language materials must be translated into Chinese
  • There is no charge for this service
  • Restrictions may apply

EIP Comments

This ability to get prioritized examination is great news for Hong Kong permanent residents and Hong Kong companies. Hong Kong could become a very strategic location for international businesses thinking of setting up an office in Asia, especially if being able to get Chinese patents granted quickly is important. International companies can also consider partnering with Hong Kong entities, since co-applicants including a Hong Kong applicant can also enjoy this new pilot program.

If you think you may be eligible for this “fast track” route and would like some help, please feel free to contact us. Our Shenzhen entity Eagle IP (Shenzhen) is a registered Chinese patent agency and we can assist with applications under this pilot program.

Official details (Chinese only) can be found here: https://www.cnipa.gov.cn/art/2022/12/23/art_53_180967.html

For more details about prioritized examination, feel free to send us an email at [email protected].

Eagle IP is a top-tier boutique patent firm with a unique mix of experienced US and Chinese patent professionals with significant cross-border knowledge and experience. Our technically expertise covers wide range of technologies including, but not limited, to life sciences, biotechnology, medicine, pharmaceuticals, material and environmental science, chemistry and consumer electronics. We have years of experiences in drafting and prosecuting patent applications involving biological deposits, sequence listings, small and large molecules, drug discovery and development, material science, software and engineering, and many others.

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

Other Articles

Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case

27 November 2023
Each year, China’s Supreme People’s Court (SPC) issues its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in the previous year. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

Compositions Limited by Use: A Cautionary Tale

26 October 2022
Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]

Burden Shift: CNIPA Requires Applicant to “Prove” that Post-Filing Data is not Fake Data

1 April 2025
“Good Faith” is a challenging concept that brings with it the nuances of a particular jurisdiction’s ideas about honesty, moral values, and societal expectations. Most patent laws around the world include good faith requirements – especially in matters involving the legal and the medical profession – and China is no exception. So what’s the standard? […]

Our Past Events

Top crossarrow-right